Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
The Readout

New woes for Portola & Axovant angst

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Sept. 19, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for September 19, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Focus Covid booster campaigns on high-risk people, WHO’s vaccine…
Focus Covid booster campaigns on high-risk people, WHO’s vaccine experts recommend
23andMe had devastating news about my health. I wish…
23andMe had devastating news about my health. I wish a person had delivered it
New guidelines on severe brain injury complicate already difficult…
New guidelines on severe brain injury complicate already difficult decisions
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories